4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Non Operating Income data on file, last reported at $4.9 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 13.97% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $18.6 million, a 30.64% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, down 27.94% from the prior year.
• Non Operating Income for Q1 2026 stood at $4.9 million, up from $4.7 million in the prior quarter.
• Over the last five years, Non Operating Income for FDMT reached as high as $7.5 million in Q2 2024 and fell as low as $54000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $3.9 million across 5 years, with a median of $4.4 million in 2023.
• Across the five-year window, Non Operating Income jumped 4757.14% in 2022 and sank 40.88% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.3 million in 2022, then jumped by 225.8% to $4.4 million in 2023, then soared by 47.54% to $6.4 million in 2024, then fell by 27.37% to $4.7 million in 2025, then increased by 3.8% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $4.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.3 million in Q3 2025.